News

Latest News:

mc2_news-image-icon-04

MC2 Therapeutics’ clinical research to be presented in four poster presentations at the European Academy of Dermatology and Venereology conference - EADV 2021

POSTED: September 29, 2021

  • Poster # P1447: A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment ...

    READ FULL ARTICLE >

mc2_news-image-icon-05

Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to WYNZORA® Cream for treatment of Plaque Psoriasis

POSTED: February 17, 2021

In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.

Events:

February 28th - 29th, 2024

MC2 Therapeutics to present at the 17th Annual European Life Sciences CEO Forum

READ MORE >

November 14th - 16th, 2023

Meet MC2 at Jefferies London Healthcare Conference

READ MORE >

May 15th - 16th, 2023

MC2 Therapeutics to present at Bio€quity Europe 2023

READ MORE >

February 7th, 2023

MC2 Therapeutics to present at the BIO CEO & Investor Conference in NYC

READ MORE >

January 9th - 12th, 2023

J.P. Morgan Healthcare Conference 2023 (San Francisco)

READ MORE >

January 8th, 2023

MC2 Therapeutics to present at the Dermatology Summit 2023 in San Francisco

READ MORE >

December 7th, 2022

MC2 Therapeutics to present at Carnegie’s Next Generation Nordic Life Science Champions Seminar 2022

READ MORE >

November 15th - 17th, 2022

MC2 Therapeutics attends the Jefferies London Healthcare Conference

READ MORE >

February 28th, 2022

MC2 exposure at PCMA Business Forum 2022

READ MORE >

August 11th, 2021

MC2 Therapeutics is proud to support National Psoriasis Action Month

READ MORE >

July 23, 2021

MC2 Therapeutics supports World Sjögren’s Day

READ MORE >